)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Blau Farmacêutica (BLAU3) investor relations material
Blau Farmacêutica Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Recurring EBITDA grew 34% year-over-year to BRL 122 million, with margin reaching 26.3%, the highest since 1Q23, and net income up 33% to BRL 63 million.
Net revenue was BRL 465 million, stable year-over-year, reflecting resilience amid capacity constraints and a challenging comparison base.
Gross margin improved for the seventh consecutive quarter, reaching 40.3%, driven by a favorable sales mix and operational optimization.
The company is transforming its product mix, expanding production lines, and investing in R&D and international growth to reduce reliance on a few products and markets.
Strategic decisions, such as not converting the Prothya loan to equity and exiting the Prothia investment, have protected the balance sheet and freed up capital.
Financial highlights
Recurring EBITDA reached BRL 122 million in Q3, up 34% year-over-year, with margin at 26.3% (+670 bps), the highest since the pandemic.
Net revenue for the quarter was BRL 465 million, stable year-over-year, but up 25% sequentially due to seasonality and normalization in the aesthetics business.
Gross profit increased 10% year-over-year to BRL 187 million, with gross margin up 380 bps to 40.3%.
Net income grew 33% year-over-year to BRL 63 million, supported by operational gains and improved margins.
Working capital increased 5% year-over-year to BRL 941 million, mainly due to higher inventories.
Outlook and guidance
Capacity expansion at current plants is expected to be completed by year-end, supporting growth through 2028; new Pernambuco plant to address long-term demand.
Medium-term plans include a 70% production volume increase, accelerated product launches, and expanded Latin American presence.
Long-term strategy targets transformational growth via capacity tripling, monoclonal antibodies, and global expansion.
Management expects improved performance in the second half, with fewer production stops and margin gains from monoclonal antibody launches.
Assess margin increase potential from Bergamo.
Detail the nature of unscheduled shutdowns.
Outline plans for Prothya investment returns.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Blau Farmacêutica earnings date
Q3 20255 Nov, 2025
Next Blau Farmacêutica earnings date
Q3 20255 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Blau Farmacêutica S.A. develops and manufactures pharmaceuticals with a focus on biotechnology-based products. Its portfolio includes hospital-use medications and therapies for oncology, nephrology, and infectious diseases. The company is headquartered in Cotia, Brazil, and its shares are listed on the B3.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage